Last reviewed · How we verify
Intravenous topotecan/cisplatin
This combination uses topotecan to inhibit topoisomerase I and cisplatin to cross-link DNA, together inducing cancer cell death through multiple mechanisms.
This combination uses topotecan to inhibit topoisomerase I and cisplatin to cross-link DNA, together inducing cancer cell death through multiple mechanisms. Used for Ovarian cancer, Small cell lung cancer, Cervical cancer.
At a glance
| Generic name | Intravenous topotecan/cisplatin |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Combination chemotherapy (topoisomerase I inhibitor + platinum alkylating agent) |
| Target | Topoisomerase I; DNA (cisplatin cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Topotecan is a topoisomerase I inhibitor that prevents DNA religation, leading to DNA damage and apoptosis. Cisplatin is a platinum-based alkylating agent that forms DNA adducts and cross-links, causing irreversible DNA damage. The combination exploits synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Ovarian cancer
- Small cell lung cancer
- Cervical cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
Key clinical trials
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma (PHASE2)
- A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008) (PHASE1, PHASE2)
- High-Risk Neuroblastoma Chemotherapy Without G-CSF (NA)
- Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer (PHASE3)
- Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation (PHASE2)
- Study of Cisplatin in Cervical Cancer Stage IVB (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous topotecan/cisplatin CI brief — competitive landscape report
- Intravenous topotecan/cisplatin updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI